[go: up one dir, main page]

AR092876A1 - Inhibidores no nucleosidos de la transcriptasa inversa - Google Patents

Inhibidores no nucleosidos de la transcriptasa inversa

Info

Publication number
AR092876A1
AR092876A1 ARP130103568A ARP130103568A AR092876A1 AR 092876 A1 AR092876 A1 AR 092876A1 AR P130103568 A ARP130103568 A AR P130103568A AR P130103568 A ARP130103568 A AR P130103568A AR 092876 A1 AR092876 A1 AR 092876A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
substituents
sra
co2rb
Prior art date
Application number
ARP130103568A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR092876A1 publication Critical patent/AR092876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Los compuestos de fórmula [1] y sus sales farmacéuticamente aceptables son útiles en la inhibición de la transcriptasa inversa del VIH, la profilaxis y el tratamiento de infección por VIH y e la profilaxis, retraso de aparición o el desarrollo, y tratamiento del SIDA. Los compuestos y sus sales se pueden emplear como ingredientes en composiciones farmacéuticas, opcionalmente en combinación con otros antivirales, inmunomoduladores, antibióticos o vacunas. Reivindicación 1: Un compuesto de la fórmula [1] o una sal farmacéuticamente aceptable del mismo en la que: M es CH₂, CH₂CH₂, CH₂CH₂CH₂, CH(CH₃), C(CH₃)₂ o C(O)N(RA); Z se selecciona entre el grupo que consiste en: piridazina, piridazinona, pirimidina, pirimidinona, pirazina, pirazinona, triazina y triazinona, cada una opcionalmente sustituida con uno o más sustituyentes hasta el número máximo permitido por la valencia seleccionados entre R⁴ y R⁵; cada R¹ se selecciona independientemente entre el grupo que consiste en: halógeno, CN, NO₂, alquilo C₁₋₄, haloalquilo C₁₋₄, alquenilo C₂₋₄, OH, O-alquilo C₁₋₄, O-haloalquilo C₁₋₄, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, SO₂RA, SO₂N(RA)RB, SO₂N(RA)C(O)RB o alquenilo C₂₋₄ sustituido con CN; R² se selecciona entre el grupo que consiste en: (1) H, (2) alquilo C₁₋₆, (3) haloalquilo C₁₋₆, (4) alquilo C₁₋₆ sustituido con 1 a 3 sustituyentes cada uno de los cuales es independientemente OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, o N(RA)C(O)C(O)N(RA)RB, (5) O-alquilo C₁₋₆ en el que el alquilo está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, o S(O)₂N(RA)RB, (6) O-haloalquilo C₁₋₆,(7) halógeno, (8) CN, (9) NO₂, (10) N(RA)RB, (11) C(O)N(RA)RB, (12) C(O)RA, (13) C(O)-haloalquilo C₁₋₆, (14) C(O)ORA, (15) OC(O)RA, (16) OC(O)N(RA)RB, (17) SRA, (18) S(O)RA, (19) S(O)₂RA, (20) S(O)₂N(RA)RB, (21) N(RA)S(O)₂RB, (22) N(RA)S(O)₂N(RA)RB, (23) N(RA)C(O)RB, (24) N(RA)C(O)N(RA)RB, (25) N(RA)C(O)-C(O)N(RA)RB, (26) N(RA)CO₂RB, (27) N(RC)RD, (28) C(O)N(RC)RD, (29) OC(O)N(RC)RD, (30) S(O)₂N(RC)RD, (31) N(RA)S(O)₂N(RC)RD, (32) N(RA)C(O)N(RC)RD, (33) N(RA)C(O)-C(O)N(RC)RD, (34) CicA, (35) -O-CicA, (36) ArilA, o (37) HetA; R³ es H, alquilo C₁₋₆, halógeno, CN, fluoroalquilo C₁₋₆, OH, O-alquilo C₁₋₆ u O-haloalquilo C₁₋₆; R⁴ y R⁵ se seleccionan cada uno independientemente entre: (1) H, (2) alquilo C₁₋₆, alquenilo C₂₋₆ o alquinilo C₂₋₆, cada uno opcionalmente sustituido con uno o más sustituyentes hasta el número máximo permitido por la valencia seleccionados entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CicB, ArilB y HetB, (3) haloalquilo C₁₋₆ opcionalmente sustituido adicionalmente con uno o más sustituyentes hasta el número máximo permitido por la valencia seleccionados entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CicB, ArilB y HetB, (4) O-alquilo C₁₋₆ en el que la parte alquilo está opcionalmente sustituida con uno o más sustituyentes hasta el número máximo permitido por la valencia seleccionados entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CicB, ArilB y HetB, (5) O-haloalquilo C₁₋₆, opcionalmente sustituido adicionalmente con uno o más sustituyentes hasta el número máximo permitido por la valencia seleccionados entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CicB, ArilB y HetB, (6) halógeno, (7) CN, (8) NO₂, (9) N(RA)RB, (10) C(O)N(RA)RB, (11) C(O)RA, (12) C(O)-haloalquilo C₁₋₆, (13) C(O)ORA, (14) OC(O)RA, (15) OC(O)N(RA)RB, (16) SRA, (17) S(O)RA, (18) S(O)₂RA, (19) S(O)₂N(RA)RB, (20) N(RA)S(O)₂RB, (21) N(RA)S(O)₂N(RA)RB, (22) N(RA)C(O)RB, (23) N(RA)C(O)N(RA)RB, (24) N(RA)C(O)-C(O)N(RA)RB, (25) N(RA)CO₂RB, (26) N(RC)RD, (27) C(O)N(RC)RD, (28) OC(O)N(RC)RD, (29) S(O)₂N(RC)RD, (30) N(RA)S(O)₂N(RC)RD, (31) N(RA)C(O)N(RC)RD, (32) N(RA)C(O)-C(O)N(RC)RD, (33) OH,(34) CicB, (35) ArilB, (36) HetB, (37) -J-CicB, (38) -J-ArilB, y (39) -J-HetB, o R⁴ y R⁵ en átomos adyacentes se pueden unir junto con los átomos a los que están unidos para formar un CicC, ArilC o HetC condensado; CicA, CicB y CicC son independientemente un carbociclilo que es un cicloalquilo C₃₋₈, un cicloalquenilo C₅₋₈, o un sistema de anillos no aromático, saturado o insaturado, bicíclico C₇₋₁₂ en el que un anillo está condensado o forma un puente con el otro anillo; en los que el carbociclilo está opcionalmente sustituido con un total de 1 a 6 sustituyentes, en los que: (i) de cero a 6 sustituyentes son cada uno independientemente: (1) halógeno, (2) CN, (3) alquilo C₁₋₆, (4) OH, (5) O-alquilo C₁₋₆, (6) haloalquilo C₁₋₆, (7) O-haloalquilo C₁₋₆, (8) alquenilo C₁₋₆, o (9) alquenilo C₁₋₆ sustituido con CN, y (ii) de cero a 2 sustituyentes son cada uno independientemente: (1) CicQ, (2) AriQ, (3) HetQ, (4) HetR, (5) J-CicQ, (6) J-AriQ, (7) J-HetQ, (8) J-HetR, (9) alquilo C₁₋₆ sustituido con CicQ, AriQ, HetQ, HetR, J-CicQ, J-AriQ, J-HetQ, o J-HetR, (10) alquenilo C₂₋₆ sustituido con CicQ, AriQ, HetQ, HetR, J-CicQ, J-AriQ, J-HetQ, o J-HetR, o (11) alquinilo C₂₋₆ sustituido con CicQ, AriQ, HetQ, HetR, J-CicQ, J-AriQ, J-HetQ, o J-HetR; ArilA, ArilB y ArilC son independientemente arilo que está opcionalmente sustituido con un total de 1 a 8 sustituyentes, en el que: (i) de cero a 8 sustituyentes son cada uno independientemente: (1) alquilo C₁₋₆, (2) haloalquilo C₁₋₆, que está opcionalmente sustituido con 1 a 3 sustituyentes adicionales cada uno de los cuales se selecciona independientemente entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, o N(RA)C(O)C(O)N(RA)RB, (3) alquilo C₁₋₆ sustituido con 1 a 3 sustituyentes cada uno de los cuales se selecciona independientemente entre OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, o N(RA)C(O)C(O)N(RA)RB, (4) alquenilo C₂₋₆, (5) alquenilo C₂₋₆ sustituido con 1 a 3 sustituyentes cada uno de los cuales es independientemente OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, o N(RA)C(O)C(O)N(RA)RB, (6) alquinilo C₂₋₆, (7) alquinilo C₂₋₆ sustituido con 1 a 3 sustituyentes cada uno de los cuales es independientemente OH, O-alquilo C₁₋₆, O-haloalquilo C₁₋₆, CN, NO₂, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO₂RA, SRA, S(O)RA, S(O)₂RA, S(O)₂N(RA)RB, N(RA)C(O)RB, N(RA)CO₂RB, N(RA)S(O)₂RB, N(RA)S(O)₂N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, o N(RA)C(O)C(O)N(RA)RB, (8) O-alquilo C₁₋₆, (9) O-haloalquilo C₁₋₆, (10) OH, (11) halógeno, (12) CN, (13) NO₂, (14) N(RA)RB, (15) C(O)N(RA)RB, (16) C(O)RA, (17) C(O)-haloalquilo C₁₋₆, (18) C(O)ORA, (19) OC(O)N(RA)RB, (20) SRA, (21
ARP130103568A 2012-10-08 2013-10-02 Inhibidores no nucleosidos de la transcriptasa inversa AR092876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08

Publications (1)

Publication Number Publication Date
AR092876A1 true AR092876A1 (es) 2015-05-06

Family

ID=49354986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103568A AR092876A1 (es) 2012-10-08 2013-10-02 Inhibidores no nucleosidos de la transcriptasa inversa

Country Status (46)

Country Link
US (3) US9469634B2 (es)
EP (3) EP3656384B1 (es)
JP (2) JP5877281B2 (es)
KR (1) KR101696128B1 (es)
CN (1) CN104822670B (es)
AP (1) AP2015008355A0 (es)
AR (1) AR092876A1 (es)
AU (1) AU2013329552B8 (es)
BR (1) BR112015007742B8 (es)
CA (1) CA2887312C (es)
CL (1) CL2015000880A1 (es)
CO (1) CO7350655A2 (es)
CR (1) CR20150183A (es)
CY (3) CY1119655T1 (es)
DK (3) DK3656384T3 (es)
DO (1) DOP2015000082A (es)
EA (1) EA033436B1 (es)
EC (1) ECSP15018618A (es)
ES (3) ES2770774T3 (es)
GE (1) GEP20186838B (es)
GT (1) GT201500088A (es)
HR (3) HRP20171819T1 (es)
HU (3) HUE048670T2 (es)
IL (1) IL238090B (es)
JO (1) JO3470B1 (es)
LT (3) LT3295942T (es)
MA (1) MA37959A2 (es)
MD (1) MD4625C1 (es)
ME (1) ME02918B (es)
MX (1) MX355040B (es)
MY (1) MY192716A (es)
NI (1) NI201500048A (es)
NO (1) NO2903977T3 (es)
NZ (1) NZ706729A (es)
PE (1) PE20151787A1 (es)
PH (1) PH12015500764B1 (es)
PL (3) PL3656384T3 (es)
PT (3) PT3656384T (es)
RS (3) RS63112B1 (es)
SG (1) SG11201502620UA (es)
SI (3) SI2903977T1 (es)
TN (1) TN2015000106A1 (es)
TW (2) TWI598343B (es)
UA (1) UA114006C2 (es)
WO (1) WO2014058747A1 (es)
ZA (1) ZA201503143B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2015036563A1 (de) 2013-09-16 2015-03-19 Bayer Pharma Aktiengesellschaft Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten
SI3125894T1 (sl) * 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
AU2016342380B2 (en) 2015-10-23 2022-04-07 President And Fellows Of Harvard College Nucleobase editors and uses thereof
IL308426B1 (en) 2016-08-03 2025-11-01 Harvard College Adenosine nucleobase editors and uses thereof
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
AU2019217875A1 (en) 2018-02-06 2020-08-20 Icahn School Of Medicine At Mount Sinai Repeat RNA as biomarkers of tumor immune response
CN120987912A (zh) 2018-04-30 2025-11-21 内尔维亚诺医药科学有限公司 作为parp7抑制剂的哒嗪酮
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
MY208106A (en) 2018-09-18 2025-04-15 Gfb Abc Llc Pyridazinones and methods of use thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
PH12021551408A1 (en) * 2018-12-18 2022-05-16 Merck Sharp & Dohme Llc Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
WO2020236692A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Pyridinone derivatives as selective cytotoxic agents against hiv infected cells
EP3982989A4 (en) 2019-06-13 2023-07-19 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2021067946A1 (en) * 2019-10-04 2021-04-08 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN114761086B (zh) 2019-10-30 2025-07-22 里邦医疗公司 作为parp7抑制剂的哒嗪酮
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
KR20230043151A (ko) 2020-07-24 2023-03-30 더 제너럴 하스피탈 코포레이션 증강된 바이러스-유사 입자 및 세포에의 전달을 위한 그의 사용 방법
US20230357766A1 (en) 2020-09-24 2023-11-09 The Broad Institute, Inc. Prime editing guide rnas, compositions thereof, and methods of using the same
AU2022206476A1 (en) 2021-01-11 2023-07-20 President And Fellows Of Harvard College Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
JP2024523646A (ja) * 2021-07-01 2024-06-28 ヤンセン ファーマシューティカ エヌ．ベー． ５－オキソ－ピリド［２，３－ｄ］ピリダジン－６（５Ｈ）－イルアセトアミド
AU2022325166A1 (en) 2021-08-06 2024-02-08 President And Fellows Of Harvard College Improved prime editors and methods of use
US20240417719A1 (en) 2021-10-25 2024-12-19 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
EP4441072A1 (en) 2021-12-03 2024-10-09 The Broad Institute Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
EP4619515A1 (en) 2022-11-17 2025-09-24 The Broad Institute, Inc. Prime editor delivery by aav
EP4662306A2 (en) 2023-02-09 2025-12-17 The Broad Institute Inc. Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease
AR133187A1 (es) 2023-07-07 2025-09-03 Merck Sharp & Dohme Llc Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US6451822B1 (en) 1998-04-27 2002-09-17 Centre National De La Recherche Scientifique 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2598404T3 (es) 2003-02-07 2017-01-27 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevención de infección por el VIH
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
BRPI0506786A (pt) 2004-01-12 2007-05-22 Gilead Sciences Inc compostos antivirais de fosfonato de pirimidila e processos de uso
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
SG152263A1 (en) 2004-04-23 2009-05-29 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
WO2006067587A2 (en) 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
JP5539216B2 (ja) * 2007-11-20 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 非ヌクレオシド系逆転写酵素阻害剤
EP2231621B1 (en) * 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
KR101421861B1 (ko) 2010-03-30 2014-07-22 머크 캐나다 인크. 비-뉴클레오시드 역전사효소 억제제
EP2558093A4 (en) 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV

Also Published As

Publication number Publication date
EP3295942B1 (en) 2019-11-20
ES2770774T3 (es) 2020-07-03
NZ706729A (en) 2018-09-28
BR112015007742B1 (pt) 2021-01-19
AU2013329552B8 (en) 2017-01-12
MD4625C1 (ro) 2019-11-30
PL3656384T3 (pl) 2022-04-04
PE20151787A1 (es) 2015-12-03
JP5877281B2 (ja) 2016-03-02
HUE058903T2 (hu) 2022-09-28
PT3656384T (pt) 2022-03-22
EP3656384A1 (en) 2020-05-27
BR112015007742A2 (pt) 2017-08-08
LT3656384T (lt) 2022-05-10
IL238090B (en) 2019-02-28
LT3295942T (lt) 2020-02-10
RS56543B1 (sr) 2018-02-28
EA201590674A1 (ru) 2016-02-29
RS59863B1 (sr) 2020-03-31
CA2887312C (en) 2017-02-28
GEP20186838B (en) 2018-04-10
TN2015000106A1 (en) 2016-06-29
DOP2015000082A (es) 2015-08-16
KR101696128B1 (ko) 2017-01-13
US20170349585A1 (en) 2017-12-07
MD4625B1 (ro) 2019-04-30
UA114006C2 (xx) 2017-04-10
PT3295942T (pt) 2020-02-18
JP2016128470A (ja) 2016-07-14
DK3295942T3 (da) 2020-02-10
PL3295942T3 (pl) 2020-05-18
JP6097422B2 (ja) 2017-03-15
CL2015000880A1 (es) 2015-08-28
DK2903977T3 (en) 2017-12-04
TW201623256A (zh) 2016-07-01
CN104822670A (zh) 2015-08-05
EP2903977B1 (en) 2017-09-20
PT2903977T (pt) 2017-11-14
SG11201502620UA (en) 2015-05-28
TWI598343B (zh) 2017-09-11
AU2013329552A1 (en) 2015-04-16
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
HK1207369A1 (en) 2016-01-29
ES2645638T3 (es) 2017-12-07
JP2015533123A (ja) 2015-11-19
HRP20171819T1 (hr) 2017-12-29
ME02918B (me) 2018-10-20
HUE048670T2 (hu) 2020-08-28
US10189831B2 (en) 2019-01-29
TWI538907B (zh) 2016-06-21
AU2013329552B2 (en) 2016-09-15
EP3295942A1 (en) 2018-03-21
EP3656384B1 (en) 2022-02-23
RS63112B1 (sr) 2022-05-31
MD20150047A2 (ro) 2015-08-31
KR20150065186A (ko) 2015-06-12
HK1252786A1 (en) 2019-05-31
US20160145255A1 (en) 2016-05-26
BR112015007742B8 (pt) 2021-03-23
ES2909190T3 (es) 2022-05-05
CY1119655T1 (el) 2018-04-04
SI3656384T1 (sl) 2022-05-31
ZA201503143B (en) 2016-06-29
SI3295942T1 (sl) 2020-03-31
CN104822670B (zh) 2018-01-12
GT201500088A (es) 2017-09-28
NI201500048A (es) 2016-06-29
SI2903977T1 (sl) 2017-12-29
JO3470B1 (ar) 2020-07-05
LT2903977T (lt) 2017-12-11
TW201420576A (zh) 2014-06-01
HRP20220502T1 (hr) 2022-05-27
DK3656384T3 (da) 2022-04-19
HUE037231T2 (hu) 2018-08-28
EP2903977A1 (en) 2015-08-12
HRP20200158T1 (hr) 2020-08-07
EA033436B1 (ru) 2019-10-31
US9469634B2 (en) 2016-10-18
CY1125202T1 (el) 2024-02-16
CY1122585T1 (el) 2021-01-27
MY192716A (en) 2022-09-05
PH12015500764B1 (en) 2019-04-05
CO7350655A2 (es) 2015-08-10
AP2015008355A0 (en) 2015-04-30
CR20150183A (es) 2015-08-10
PH12015500764A1 (en) 2015-07-27
AU2013329552C1 (en) 2016-12-22
ECSP15018618A (es) 2019-06-30
CA2887312A1 (en) 2014-04-17
WO2014058747A1 (en) 2014-04-17
US9718819B2 (en) 2017-08-01
PL2903977T3 (pl) 2018-01-31
MA37959A2 (fr) 2017-12-29
NO2903977T3 (es) 2018-02-17
US20140100231A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR117189A1 (es) Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
AR115885A1 (es) Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
MX376433B (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR115131A1 (es) Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
MX375789B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de hepatitis b.
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX384426B (es) Proceso para preparar derivados de fenil sulfamoilpirrolamidas
AR104326A1 (es) Compuestos nucleósidos 5-sustituidos
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
PE20141351A1 (es) Triazolopiridinas
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
DOP2018000135A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR116947A1 (es) Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos

Legal Events

Date Code Title Description
FG Grant, registration